New program aims to boost medication adherence for breast cancer patients in rwanda

NCT ID NCT07562399

Not yet recruiting Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a program to help women with ER-positive breast cancer in Rwanda take their daily hormone therapy as prescribed. The program includes education, reminders, and behavioral support. Researchers will measure how well participants stick with their medication and how it affects their quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer Medication Adherence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER MEDICATION ADHERENCE

Contacts and locations

Locations

Boston Children's Hospital

Boston, Massachusetts, 02115, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02053, United States
Butaro Cancer Center of Excellence

Butaro, RN8, 02053, Rwanda
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.